Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02400801

Enrollment

166

Registered

2015-03-27

Start date

2013-06-30

Completion date

2018-01-26

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Infertility

Keywords

endometriosis, infertility, assisted reproductive technology

Brief summary

Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? (A single centre randomised controlled trial)

Interventions

DRUGtriptorelin

gonadotropin-releasing hormone (GnRH) agonist

DRUGethinylestradiol + dienogest

oral oestroprogestogen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Inclusion criteria

* histologically proven endometriosis with complete treatment of all endometriosis lesions during laparoscopy * only first three ART cycles * normal uterine cavity * Eligible for ovarian stimulation with long agonist protocol

Exclusion criteria

* FSH\>20 IU/L * presence of large intramural fibroids (\> 3 cm) * \<4 oocytes obtained in any previous fresh ART cycle * ART with sperm derived from testicular biopsy * ART with Preimplantation Genetic Diagnosis/Screening

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate per initiated ART cycle	participants will be followed for the duration of the ART cycle including the pregnancy test, an expected average of 10 weeks in the active comparator group and an expected average of 18 weeks in the experimental group

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026